 |
|
|
|
Ruze supply good service, thanks.
 |
—— Gaurav
- I'm Online Chat Now
Tyrosine kinase receptor inhibitor Antineoplastic afatinib CAS:850140-72-6
Product Details:
Payment & Shipping Terms:
|
Detailed Product Description
| Product Name: | Afatinib | CAS: | 850140-72-6 |
|---|---|---|---|
| MF: | C24H25ClFN5O3 | MW: | 485.9384032 |
| Mol File: | 850140-72-6.mol |
Weifang Ruze New Material Co.,LTD a China supplier of Afatinib (CAS No.: 850140-72-6),CAS 850140-72-6offers for your requirements of RND, evaluation, pilots and commercial along with supportive technical package required for evaluation.
afatinib
[[PRODUCT NAME]:afatinib
[CATALOG NUMBER]:
[STRUCTURE]:
[CAS NUMBER]:850140-72-6
[MOLECULAR FORMULA]:C24H25ClFN5O3
[MOLECULAR WEIGHT]:485.93800
[BATCH NO]:20190224
[TEST]:SPECIFICATION
[APPEARANCE] :White Powder
[ASSAY]:99%min
[WATER]:0.5%max
Afatinib Chemical Properties
| density | 1.380 |
| form | Yellow powder. |
Safety Information
| HS Code | 29420000 |
Afatinib Usage And Synthesis
| General Description | Afatinib is a prescription medicine that can be taken orally for the treatment of non-small cell lung cancer (NSCLC) with atypical Epidermal Growth Factor Receptor (EFGR) agents. Afatinib is also prescribed for the treatment of NSCLC with the potential or radiating to other body tissues other than the lungs (metastatic cancer) as detected through an FDA approved examination. Afatinib is a 4-anilinoquinazoline tyrosine kinase suppressor that is available as a dimaleate salt (brand name: Giltrif). The drug is the first FDA-endorsed oncology product by Boehringer Ingelheim. |
| Indication | The drug is a kinase agonist that is indicated as monotherapy for EFGR and tyrosine kinase suppressor-naive adult patients whose NSCLC is metastatic or locally advanced and the tumours are resistant to EGFR mutations as approved by an FDA-endorsed examination. In addition, the adult patients should indicate signs of squamous histology progress at the time of platinum-based chemotherapy or after the sessions. |
| Information on Dosing | The recommended dose of Afatinib is 40mg administered orally once every day 1-2 hours after the consumption of a meal, until the tumours regress or if the patient’s body can no longer tolerate the drug. |
| Pharmacodynamics | Afatinib is an irreversible ErbB inhibitor that forms covalent bonds with the kinase domains of EGFR, HER4, and human EGFRs (HER) 2, which results in an irreparable obstruction of tyrosine kinase autophosphorylation. |
Weifang Ruze New Material Co.,LTD supply free sample and datebase on Afatinib (CAS No.: 850140-72-6), if you want futher information about Afatinib (CAS No.: 850140-72-6), please feel free to contract us.
Contact Details
Weifang Ruze New Material Co., Ltd.
Contact Person: Ruze02
Other Products
-
Repaglinide Treatment Of Diabetes Medical Intermediate Cas 135062-02-1
-
Sitagliptin Treatment Of Type 2 Diabetes Pharma Intermediates Cas 486460-32-6
-
Sitagliptin Phosphate Monohydrate Treatment Of Type 2 Diabetes Cas 654671-77-9
-
Empagliflozin Treatment Of Type 2 Diabetes Pharmaceutical Intermediates Cas 864070-44-0
-
Antineoplastic Chemotherapy Drugs Ap26113 Cas 1197958-12-5 Assay 99%
-
Ibrutinib Antineoplastic Drugs Cas 936563-96-1 White Crystal Powder